(BDX) Becton Dickinson - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0758871091
Stock: Medical Devices, Lab Equipment, Diagnostics, Surgical Products, Drug Delivery
Total Rating 41
Risk 70
Buy Signal -0.77
| Risk 5d forecast | |
|---|---|
| Volatility | 22.5% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -13.01 |
| Character TTM | |
|---|---|
| Beta | 0.479 |
| Beta Downside | 0.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.06% |
| CAGR/Max DD | -0.02 |
EPS (Earnings per Share)
Revenue
Description: BDX Becton Dickinson March 03, 2026
Becton, Dickinson and Company (NYSE: BDX) is a global medical technology firm that develops and manufactures a broad portfolio of medical supplies, laboratory equipment, and diagnostic products. Operating through segments such as Medical Essentials, Connected Care, and Life Sciences, the company produces foundational healthcare tools ranging from IV catheters and hypodermic syringes to advanced infusion pumps and automated medication dispensing systems. BDX benefits from a business model heavily reliant on high-volume consumables, creating recurring revenue streams alongside its capital equipment sales within the Health Care Equipment industry.
The company serves healthcare institutions, life science researchers, and the pharmaceutical industry with specialized technologies, including flow cytometry analyzers, molecular testing assays, and prefillable drug delivery systems. Its surgical and interventional offerings encompass soft tissue repair grafts, infection prevention products, and urology solutions. BDX also maintains strategic collaborations, such as its partnership with ChemoGLO, to enhance safety protocols regarding hazardous drug contamination. For comprehensive data on BDXs financial performance and fair value estimates, investors can check ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 1.95% < 20% (prev 4.82%; Δ -2.87% < -1%) |
| CFO/TA 0.06 > 3% & CFO 3.39b > Net Income 1.76b |
| Net Debt (18.52b) to EBITDA (5.10b): 3.63 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (285.1m) vs 12m ago -1.83% < -2% |
| Gross Margin: 45.76% > 18% (prev 0.45%; Δ 4531 % > 0.5%) |
| Asset Turnover: 40.04% > 50% (prev 37.76%; Δ 2.28% > 0%) |
| Interest Coverage Ratio: 4.65 > 6 (EBITDA TTM 5.10b / Interest Expense TTM 565.0m) |
Altman Z'' 1.91
| A: 0.01 (Total Current Assets 9.19b - Total Current Liabilities 8.76b) / Total Assets 54.84b |
| B: 0.30 (Retained Earnings 16.70b / Total Assets 54.84b) |
| C: 0.05 (EBIT TTM 2.63b / Avg Total Assets 54.75b) |
| D: 0.52 (Book Value of Equity 15.24b / Total Liabilities 29.56b) |
| Altman-Z'' Score: 1.91 = BBB |
Beneish M -3.12
| DSRI: 0.90 (Receivables 2.51b/2.64b, Revenue 21.92b/20.64b) |
| GMI: 0.99 (GM 45.76% / 45.22%) |
| AQI: 0.98 (AQ_t 0.71 / AQ_t-1 0.72) |
| SGI: 1.06 (Revenue 21.92b / 20.64b) |
| TATA: -0.03 (NI 1.76b - CFO 3.39b) / TA 54.84b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of BDX shares?
As of March 06, 2026, the stock is trading at USD 169.94 with a total of 2,519,087 shares traded.
Over the past week, the price has changed by -3.80%, over one month by +4.67%, over three months by +12.05% and over the past year by -1.46%.
Over the past week, the price has changed by -3.80%, over one month by +4.67%, over three months by +12.05% and over the past year by -1.46%.
Is BDX a buy, sell or hold?
Becton Dickinson has received a consensus analysts rating of 3.59.
Therefor, it is recommend to hold BDX.
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 197.2 | 16% |
| Analysts Target Price | 197.2 | 16% |
BDX Fundamental Data Overview March 05, 2026
P/E Trailing = 28.5123
P/E Forward = 13.6986
P/S = 2.8788
P/B = 1.9864
P/EG = 1.3307
Revenue TTM = 21.92b USD
EBIT TTM = 2.63b USD
EBITDA TTM = 5.10b USD
Long Term Debt = 16.92b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from shortTermDebt, last quarter)
Debt = 19.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.52b USD (from netDebt column, last quarter)
Enterprise Value = 81.91b USD (63.12b + Debt 19.54b - CCE 740.0m)
Interest Coverage Ratio = 4.65 (Ebit TTM 2.63b / Interest Expense TTM 565.0m)
EV/FCF = 31.13x (Enterprise Value 81.91b / FCF TTM 2.63b)
FCF Yield = 3.21% (FCF TTM 2.63b / Enterprise Value 81.91b)
FCF Margin = 12.00% (FCF TTM 2.63b / Revenue TTM 21.92b)
Net Margin = 8.01% (Net Income TTM 1.76b / Revenue TTM 21.92b)
Gross Margin = 45.76% ((Revenue TTM 21.92b - Cost of Revenue TTM 11.89b) / Revenue TTM)
Gross Margin QoQ = 44.63% (prev 47.50%)
Tobins Q-Ratio = 1.49 (Enterprise Value 81.91b / Total Assets 54.84b)
Interest Expense / Debt = 0.55% (Interest Expense 107.0m / Debt 19.54b)
Taxrate = 21.56% (105.0m / 487.0m)
NOPAT = 2.06b (EBIT 2.63b * (1 - 21.56%))
Current Ratio = 1.05 (Total Current Assets 9.19b / Total Current Liabilities 8.76b)
Debt / Equity = 0.77 (Debt 19.54b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 3.63 (Net Debt 18.52b / EBITDA 5.10b)
Debt / FCF = 7.04 (Net Debt 18.52b / FCF TTM 2.63b)
Total Stockholder Equity = 25.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.21% (Net Income 1.76b / Total Assets 54.84b)
RoE = 6.93% (Net Income TTM 1.76b / Total Stockholder Equity 25.35b)
RoCE = 6.22% (EBIT 2.63b / Capital Employed (Equity 25.35b + L.T.Debt 16.92b))
RoIC = 4.61% (NOPAT 2.06b / Invested Capital 44.68b)
WACC = 5.64% (E(63.12b)/V(82.65b) * Re(7.25%) + D(19.54b)/V(82.65b) * Rd(0.55%) * (1-Tc(0.22)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.09%
[DCF] Terminal Value 87.38% ; FCFF base≈2.75b ; Y1≈3.08b ; Y5≈4.09b
[DCF] Fair Price = 358.4 (EV 120.46b - Net Debt 18.52b = Equity 101.95b / Shares 284.5m; r=5.90% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 60.25 | EPS CAGR: -2.34% | SUE: -2.35 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 2.72% | SUE: 2.08 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.07 | Chg7d=+0.000 | Chg30d=-0.926 | Revisions Net=-7 | Analysts=11
EPS current Year (2026-09-30): EPS=12.54 | Chg7d=+0.000 | Chg30d=-2.398 | Revisions Net=-10 | Growth EPS=-12.9% | Growth Revenue=-11.9%
EPS next Year (2027-09-30): EPS=13.50 | Chg7d=+0.008 | Chg30d=-2.352 | Revisions Net=-11 | Growth EPS=+7.6% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = -15.3% (Analyst -10.8% - Implied 4.4%)
P/E Forward = 13.6986
P/S = 2.8788
P/B = 1.9864
P/EG = 1.3307
Revenue TTM = 21.92b USD
EBIT TTM = 2.63b USD
EBITDA TTM = 5.10b USD
Long Term Debt = 16.92b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from shortTermDebt, last quarter)
Debt = 19.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.52b USD (from netDebt column, last quarter)
Enterprise Value = 81.91b USD (63.12b + Debt 19.54b - CCE 740.0m)
Interest Coverage Ratio = 4.65 (Ebit TTM 2.63b / Interest Expense TTM 565.0m)
EV/FCF = 31.13x (Enterprise Value 81.91b / FCF TTM 2.63b)
FCF Yield = 3.21% (FCF TTM 2.63b / Enterprise Value 81.91b)
FCF Margin = 12.00% (FCF TTM 2.63b / Revenue TTM 21.92b)
Net Margin = 8.01% (Net Income TTM 1.76b / Revenue TTM 21.92b)
Gross Margin = 45.76% ((Revenue TTM 21.92b - Cost of Revenue TTM 11.89b) / Revenue TTM)
Gross Margin QoQ = 44.63% (prev 47.50%)
Tobins Q-Ratio = 1.49 (Enterprise Value 81.91b / Total Assets 54.84b)
Interest Expense / Debt = 0.55% (Interest Expense 107.0m / Debt 19.54b)
Taxrate = 21.56% (105.0m / 487.0m)
NOPAT = 2.06b (EBIT 2.63b * (1 - 21.56%))
Current Ratio = 1.05 (Total Current Assets 9.19b / Total Current Liabilities 8.76b)
Debt / Equity = 0.77 (Debt 19.54b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 3.63 (Net Debt 18.52b / EBITDA 5.10b)
Debt / FCF = 7.04 (Net Debt 18.52b / FCF TTM 2.63b)
Total Stockholder Equity = 25.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.21% (Net Income 1.76b / Total Assets 54.84b)
RoE = 6.93% (Net Income TTM 1.76b / Total Stockholder Equity 25.35b)
RoCE = 6.22% (EBIT 2.63b / Capital Employed (Equity 25.35b + L.T.Debt 16.92b))
RoIC = 4.61% (NOPAT 2.06b / Invested Capital 44.68b)
WACC = 5.64% (E(63.12b)/V(82.65b) * Re(7.25%) + D(19.54b)/V(82.65b) * Rd(0.55%) * (1-Tc(0.22)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.09%
[DCF] Terminal Value 87.38% ; FCFF base≈2.75b ; Y1≈3.08b ; Y5≈4.09b
[DCF] Fair Price = 358.4 (EV 120.46b - Net Debt 18.52b = Equity 101.95b / Shares 284.5m; r=5.90% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 60.25 | EPS CAGR: -2.34% | SUE: -2.35 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 2.72% | SUE: 2.08 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.07 | Chg7d=+0.000 | Chg30d=-0.926 | Revisions Net=-7 | Analysts=11
EPS current Year (2026-09-30): EPS=12.54 | Chg7d=+0.000 | Chg30d=-2.398 | Revisions Net=-10 | Growth EPS=-12.9% | Growth Revenue=-11.9%
EPS next Year (2027-09-30): EPS=13.50 | Chg7d=+0.008 | Chg30d=-2.352 | Revisions Net=-11 | Growth EPS=+7.6% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = -15.3% (Analyst -10.8% - Implied 4.4%)